Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Int J Cancer. 2009 Nov 15;125(10):2465–2473. doi: 10.1002/ijc.24628

Figure 4. Effect of fisetin treatment of AsPC-1 cells on the protein expression of MMP9, XIAP, reporter activity of MMP9 and NF-κB and on the activity of MMP9.

Figure 4

(A). Histogram shows the effect of fisetin (0-40 μM) treatment of AsPC-1 cells on NF-κB reporter activity. Data is represented as mean ± SE of three independent experiments. (B) Representative immunoblots showing effect of fisetin (0-40 μM) treatment on protein expression of MMP9 and XIAP. Equal loading was confirmed by stripping immunoblots and reprobing them for β-actin. (C) Histogram shows the effect of fisetin (0-40 μM) treatment of AsPC-1 cells on promoter activity of MMP9. Fisetin treated cells were transfected with 1 μg of MMP9 luciferase reporter plasmid or 50 ng of renilla luciferase reporter plasmid as an internal control as described in Materials and Methods. Data is represented as mean ± SE of three independent experiments. (D) A representative zymogram showing MMP9 activity in AsPC-1 cells treated with fisetin (0-40 μM). *indicates p<0.05.